LONG® EGF is a recombinant analog of human epidermal growth factor (EGF) used in regulatory approved cell-based therapies. It was developed as a supplement for use in therapeutic cell culture applications as a like-for-like replacement for native EGF or recombinant human EGF (hEGF). The source is a proprietary Escherichia coli fermentation process, manufactured without the use of animal- or human-derived materials.
Lyophilized powder dried from 10 mM hydrochloric acid (HCl) in an atmosphere of nitrogen at a slight vacuum (~25 kPa)
Under a quality management system that is ISO:9001 certified and based on EU GMP
Proprietary e.coli manufacturing process
Positive effects have been observed with LONG®R3 IGF-I in HEK293, MDCK and HeLa cell lines
LONG® EGF can be used as a supplement for serum-free or low serum culture.
Recombinant LONG® EGF acts via the Erb-1 receptor and has applications in fibroblast cell culture. Synergistic effects have been observed with LONG®R3 IGF-I in HEK293, MDCK and HeLa cell lines.
LONG® EGF is used across a wide range of customer-driven applications, including: